Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

OTLK

Outlook Therapeutics Inc

1.40

Jul 24 • 3:59 PM ET +0.08 (6.44%)

1.40

Aftermarket • 7:59 PM ET -0.00 (-0.36%)

Healthcare Biotechnology USA Micro NASD

Jul 24, 2:01 PMEarly FDA approval of LYTENAVA for wet AMD triggers 24% OTLK surge

Peers: XLO RADX RNTX TELO INDP GLSI PALI PRLD RZLT TARA

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	262.73M
Enterprise Value	282.17M
Income	-43.44M
Sales	1.51M
Book/sh	-0.28
Cash/sh	0.04
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Jun 14, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	173.99
P/B	-
P/C	33.90
P/FCF	-
EV/EBITDA	-
EV/Sales	186.87
Quick Ratio	0.45
Current Ratio	0.54
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.09
EPS next Y	-0.27
EPS next Q	-0.11
EPS this Y	72.02%
EPS next Y	46.28%
EPS next 5Y	-
EPS past 3/5Y	33.96% 33.18%
Sales past 3/5Y	- -
EPS Y/Y TTM	86.28%
Sales Y/Y TTM	-
EPS Q/Q	-107.59%
Sales Q/Q	-
Earnings	May 15 AMC
EPS/Sales Surpr.	-32.01% -97.08%

Insider Own	18.78%
Insider Trans	35.13%
Inst Own	6.02%
Inst Trans	4.97%
ROA	-125.04%
ROE	-
ROIC	-
Gross Margin	63.07%
Oper. Margin	-4824.52%
Profit Margin	-2885.82%
SMA20	-7.21%
SMA50	24.87%
SMA200	49.39%
Trades

Shs Outstand	187.00M
Shs Float	151.89M
Short Float	7.40%
Short Ratio	0.57
Short Interest	11.24M
52W High	3.39 -58.55%
52W Low	0.16 772.13%
Volatility	17.65% 13.85%
ATR (14)	0.20
RSI (14)	50.84
Beta	0.83
Rel Volume	2.96
Avg Volume	19.58M
Volume	57,886,697

Perf Week	1.08%
Perf Month	-16.37%
Perf Quarter	389.72%
Perf Half Y	175.49%
Perf YTD	-11.08%
Perf Year	-29.75%
Perf 3Y	-95.82%
Perf 5Y	-97.10%
Perf 10Y	-99.73%
Recom	1.67
Target Price	8.00
Prev Close	1.32
Price	1.40
Change	6.44%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-26	Downgrade	BTIG Research	Buy → Neutral
Aug-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-25	Downgrade	Guggenheim	Buy → Neutral
Dec-02-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Mar-27-24	Upgrade	BTIG Research	Neutral → Buy	$50
Feb-15-24	Upgrade	Chardan Capital Markets	Neutral → Buy	$3
Jan-25-24	Upgrade	Guggenheim	Neutral → Buy
Dec-27-23	Upgrade	CapitalOne	Equal Weight → Overweight	$5
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral	$5 → $1
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$4.50 → $1
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight	$5
Apr-03-23	Initiated	Guggenheim	Buy	$5
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight	$4
Oct-31-22	Initiated	BTIG Research	Buy	$7
Sep-13-22	Initiated	Chardan Capital Markets	Buy	$10
Sep-11-19	Initiated	Ladenburg Thalmann	Buy	$9

Show Previous Ratings

Jul-24-26 08:30PM	FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions (Stocktwits) +6.44%
07:47PM	OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab (Stocktwits)
02:40PM	Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD (GlobeNewswire)
Jul-23-26 01:00PM	OTLK Stock Generates Buzz Ahead Of FDA Decision On Wet AMD Therapy Retail Says Favorable Verdict Could Cause A Big Boom (Stocktwits)
Jun-16-26 01:47PM	OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision (Stocktwits) +35.34%
08:02AM	Loading…
08:02AM	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA (bevacizumab-vikg) as a Treatment for Wet AMD (GlobeNewswire)
Jun-01-26 01:05PM	OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal (Stocktwits) +15.48%
08:46AM	Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
May-28-26 04:00PM	Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +26.39%
01:38PM	OTLK Stock Rocket Nearly 140%: Lytenava Dispute Resolution With FDA Pushes Stock On Track For Best Week On Record (Stocktwits)
May-27-26 01:10AM	Why RDW, TE, OTLK Stocks Posted Double-Digit Gains On Tuesday (Stocktwits) +46.30%
May-26-26 09:08AM	OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone Whats Behind This Massive Rally? (Stocktwits) +29.14%
07:00AM	Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
May-15-26 04:05PM	Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-23-26 04:05PM	Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering (GlobeNewswire) +9.83%
08:30AM	Loading…
Apr-22-26 08:30AM	Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.14%
Apr-21-26 09:05AM	Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire) -13.68%
Apr-07-26 08:50AM	Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab-vikg) Accepted by FDA (GlobeNewswire) +6.18%
Mar-25-26 04:05PM	Outlook Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire)
Mar-24-26 07:00AM	Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -38.06%
Mar-23-26 05:30PM	Outlook Therapeutics Announces Proposed Public Offering (GlobeNewswire) -8.91%
Mar-16-26 08:05AM	Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note (GlobeNewswire) -10.69%
Mar-05-26 04:15PM	Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
Feb-19-26 09:00AM	Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA (bevacizumab gamma) in Switzerland (GlobeNewswire) +6.10%
Feb-17-26 09:15AM	Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -13.82%
08:05AM	Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-11-26 08:45AM	Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter (GlobeNewswire) +11.52%
Jan-07-26 09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks) +11.43%
Jan-06-26 08:35AM	Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development (GlobeNewswire)
Jan-02-26 07:29AM	Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks (Investing.com) -58.23%
04:35PM	Loading…
Jan-01-26 04:35PM	FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present form (TipRanks)
Dec-31-25 04:15PM	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire) -15.28% -58.23%
Dec-26-25 05:00PM	Outlook Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +8.79%
Dec-19-25 09:30AM	Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 (GlobeNewswire)
Dec-16-25 11:39AM	Micron Dominates Barchart's Top 100 with Killer VolumeYour Buy Signal? (Barchart) +13.82%
Nov-24-25 09:05AM	Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 08:30AM	Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) +14.84%
Nov-03-25 08:35AM	Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 (GlobeNewswire)
Sep-29-25 08:45AM	Outlook Therapeutics Provides Update on Type A Meeting with FDA (GlobeNewswire) +9.27%
Sep-03-25 08:35AM	Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) (GlobeNewswire)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:35AM	Outlook Therapeutics Requests Type A Meeting with FDA (GlobeNewswire)
Aug-29-25 10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks) -21.91%
09:38AM	Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
Aug-28-25 11:15AM	FDA Rejects Outlook Therapeutics Eye Drug For Second Time (Benzinga) -54.11%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
06:30AM	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +18.38%
Aug-14-25 09:15AM	Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +14.08%
08:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Jul-30-25 05:50AM	New Strong Buy Stocks for July 30th (Zacks)
Jul-24-25 09:00AM	Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase (GlobeNewswire)
Jul-22-25 08:45AM	Outlook Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-01-25 08:05AM	Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer (GlobeNewswire)
Jun-18-25 09:05AM	Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event (GlobeNewswire)
Jun-11-25 05:06AM	Outlooks wet AMD treatment accepted by SMC for NHS Scotland (Pharmaceutical Technology)
Jun-10-25 08:05AM	Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire)
Jun-02-25 07:00AM	Outlook Therapeutics Announces Commercial Launch of LYTENAVA (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD (GlobeNewswire)
May-23-25 06:30AM	Outlook Therapeutics Announces Pricing of $13.0 Million Public Offering (GlobeNewswire)
May-22-25 04:01PM	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
May-15-25 04:01PM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Apr-08-25 08:45AM	Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
Mar-20-25 05:24PM	Outlook Therapeutics files to sell 21.72M shares of common stock for holders (SeekingAlpha)
Feb-28-25 08:05AM	Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration (GlobeNewswire) +8.70%
Feb-19-25 09:00AM	Outlook Therapeutics Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-14-25 08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update (GlobeNewswire)
Feb-04-25 09:05AM	Outlook Therapeutics Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Jan-31-25 08:05AM	Outlook Therapeutics Appoints Faisal G. Sukhtian as Chairman of the Board of Directors (GlobeNewswire)
Jan-23-25 09:05AM	Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD (GlobeNewswire)
Jan-22-25 09:05AM	Outlook Therapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) -8.93%
Jan-16-25 12:09PM	Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug (Benzinga)
06:00AM	Outlook Therapeutics Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial (GlobeNewswire)
Jan-08-25 09:15AM	Outlook Therapeutics Participates in Virtual Investor What This Means Segment (GlobeNewswire) -5.22%
Dec-30-24 07:45AM	Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss (GuruFocus.com) -7.46%
Dec-28-24 10:50PM	Outlook Therapeutics Reports 2024 Financial Results (TipRanks)
08:10AM	Outlook Therapeutics provides ONS-5010/LYTENAVA update (TipRanks)
Dec-27-24 08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire) +18.24%
Dec-13-24 04:30PM	Outlook Therapeutics Streamlines Operations (GlobeNewswire)
Dec-04-24 08:05AM	Outlook Therapeutics Announces NICE Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire) -8.03%
Dec-03-24 04:30PM	Outlook Therapeutics Announces Executive Leadership Transition (GlobeNewswire) -11.08%
Nov-30-24 05:50AM	Outlook Therapeutics price target lowered to $9 from $50 at BTIG (TipRanks)
Nov-27-24 11:08AM	Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial (Pharmaceutical Technology) -65.24%
11:07AM	Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial (Clinical Trials Arena)
09:27AM	Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? (Benzinga)
06:50AM	Outlook Therapeutics Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial (GlobeNewswire)
Nov-06-24 08:05AM	Outlook Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Oct-17-24 09:00AM	Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment (GlobeNewswire)
Sep-16-24 08:05AM	Outlook Therapeutics to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) -8.35%
Sep-13-24 09:05AM	Outlook Therapeutics Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series (GlobeNewswire)
Sep-04-24 08:35AM	Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial (GlobeNewswire) +9.12%
Sep-03-24 08:45AM	Outlook Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -8.30%
Aug-15-24 06:20AM	Q3 2024 Outlook Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-24 07:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire) -5.29%
Aug-12-24 09:05AM	Outlook Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-09-24 07:16AM	Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now? (Insider Monkey)
Aug-07-24 08:35AM	Outlook Therapeutics to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast (GlobeNewswire)
Jul-30-24 09:10AM	Outlook Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-08-24 08:35AM	Outlook Therapeutics Announces UK MHRA Marketing Authorization of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire) +7.38%

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

PresidentMr. Robert Charles Jahr

EVPMr. Lawrence A. Kenyon CPA

Senior Vice President of Licensing and M&AMr. Joel Prieve

Senior Vice President of Medical AffairsDr. Surendra Sharma M.D.

Senior Vice President of Clinical Development & Regulatory AffairsDr. Jennifer M. Kissner Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Haddadin Yezan Munther	Director	Jun 02 '26	Buy	0.83	29,000	24,145	66,167	Jun 03 06:03 PM
Sukhtian Ghiath M.	Director	May 28 '26	Buy	0.59	8,539,709	5,000,000	22,092,068	Jun 01 09:30 PM
Sukhtian Faisal Ghiath	Director	May 27 '26	Buy	0.41	122,174	50,006	125,574	May 27 03:29 PM
Haddadin Yezan Munther	Director	May 26 '26	Buy	0.44	34,000	14,960	37,167	May 27 03:24 PM
THURMAN RANDY H	Director	May 26 '26	Buy	0.43	5,000	2,145	5,593	May 27 03:20 PM
HILZINGER KURT J	Director	May 26 '26	Buy	0.44	400,000	176,520	423,655	May 27 03:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OTLK

Outlook Therapeutics Inc

Upgrade your Finviz experience